Top Banner
HSCT in a patient with hyper IgM syndrome - our recent experience - Aleš Janda, Renata Formánková Department of Immunology Clinic of Paediatric Haematology and Oncology 2nd Medical School of Charles University University Hospital Motol, Prague
19

HSCT in a patient with hyper IgM sy n drome - our recent experience -

Jan 12, 2016

Download

Documents

Ken

HSCT in a patient with hyper IgM sy n drome - our recent experience -. Aleš Janda, Renata Formánková Department of Immunology Clinic of Paediatric Haematology and Oncology 2nd Medical School of Charles University University Hospital Motol, Prague. ONDŘEJ, 8 month old boy. - PowerPoint PPT Presentation
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: HSCT in a patient with hyper IgM sy n drome  - our recent experience  -

HSCT in a patient with hyper IgM syndrome

- our recent experience -

Aleš Janda, Renata Formánková

Department of Immunology

Clinic of Paediatric Haematology and Oncology 2nd Medical School of Charles University

University Hospital Motol, Prague

Page 2: HSCT in a patient with hyper IgM sy n drome  - our recent experience  -

ONDŘEJ, 8 month old boy

Page 3: HSCT in a patient with hyper IgM sy n drome  - our recent experience  -

ONDŘEJ Personal history

vaccinated with BCG in 3 months lymphnode

enlargement in armpit suppuration puncture healing

in 4 months cough runny yellow-green stool longterm

since 2 month of age failure to thrive

Page 4: HSCT in a patient with hyper IgM sy n drome  - our recent experience  -

ONDŘEJ Growth chart

Page 5: HSCT in a patient with hyper IgM sy n drome  - our recent experience  -

ONDŘEJ Symptoms at diagnosis

in 8 months thrush in oral cavity

afebrile, weight loss ( 200 g from check-up in 6 months), tachypnoea

sat. O2 80%, leukocytosis 37 x109/l, Hgb 10,4 g/dl, trombocytosis 837x109/l

ESR, CRP

Page 6: HSCT in a patient with hyper IgM sy n drome  - our recent experience  -

ONDŘEJ Microbial investigation

PCR CMV blood + BAL + PCR Pneumocystis carinii blood + BAL

+ PCR mycobacteria blood - BAL - test of stool on Cryptosporidia negative

Page 7: HSCT in a patient with hyper IgM sy n drome  - our recent experience  -

ONDŘEJ Immunological investigation

IgG 0,6 g/l [NR 3.6-7.7]IgA < 0.06 g/l [NR 0.1-0.6]IgE < 1 IU/ml [NR 0-30.0]IgM 1,98 g/l [NR 0.3-1.4]

number of lymphocytesfunctional tests

(blastic transformation) (NBT)

normal

Page 8: HSCT in a patient with hyper IgM sy n drome  - our recent experience  -

ONDŘEJ Flow Cytometry

Page 9: HSCT in a patient with hyper IgM sy n drome  - our recent experience  -

Mutation in 5th exonu of CD40L geneAminoacid substitution Tre254Met(dr. Genevieve de Saint Basil, Neckar, Pařiž)

Notarangelo, J Allergy Clin Immunol 2006, 117, 855-64

Xq26

Molecular genetics

Mother is carrier

ONDŘEJ

Page 10: HSCT in a patient with hyper IgM sy n drome  - our recent experience  -

Defects in HIGM

Notarangelo, J Allergy Clin Immunol 2006, 117, 855-64

X

X

XXX

X

Page 11: HSCT in a patient with hyper IgM sy n drome  - our recent experience  -

Clinical symptoms insufficient antibody production bacterial inf.

defect of cooperation T-DC opportunist, viral inf.

Defect in negative selection of autoreactive clones in thymus autoimmunity

antigenic stimulation (inf.) inaccurate regulation

tumours

Page 12: HSCT in a patient with hyper IgM sy n drome  - our recent experience  -

HIGM1 Treatment and prognosis

regular IVIG substitution prevention of pneumocystic pneumonia:

cotrimoxazol in case of neutropenia: G-CSF prevention of cryptosporidial infection: hygienic

regime, use of boiled water in case of malabsorbtion: total parenteral nutrition sometimes liver transplantation needed only 40 % of patients reach 25 years of age

HSCT is curativeGennery, Blood 2004,103, 1152-1157

Page 13: HSCT in a patient with hyper IgM sy n drome  - our recent experience  -

ONDŘEJ Supportive therapy

trimetoprim 20 mg/kg/day ganciclovir for 3 weeks antimycotics (fluconazol) azitromycin to prevent cryptosporidial infection antiTBC drugs (INH, RIF) to prevent BCG infection IVIG 0.5g/kg every 3-4 weeks G-CFS if ANC < 1000

indicated for allogeneic SCT from identical sibling

Page 14: HSCT in a patient with hyper IgM sy n drome  - our recent experience  -

ONDŘEJ January 2007 – before SCT

no signs of respiratory infection

good oral intake, no diarrhea, but persistent failure to thrive (7,5 kg)

no signs of cryptosporidial infection, normal hepatic function and ultrasound imaging

Chest X-RAY - slight residual interstitial changes

Page 15: HSCT in a patient with hyper IgM sy n drome  - our recent experience  -

ONDŘEJ Stem cell transplantation I

February 9, 2007 (aged 12,5 months)

Donor: HLA identical sister (16 years) Graft: BM (NC 8,6x108/kg, CD34+ 11,5x106/kg)

Conditioning: Busulfan (20mg/kg)Cyclophosphamide (200mg/kg)

GVHD prophylaxis: Cyclosporine A, Methotrexate

Page 16: HSCT in a patient with hyper IgM sy n drome  - our recent experience  -

ONDŘEJ Stem cell transplantation II

Engraftment: ANC D+21, Plt D+20

GVHD: gr. II (skin 3, GIT 1) on D+28therapy: corticosteroids 2mg/kg

Complications: febrile neutropenia (D+11)CMV infection (D+32) – GCV

Discharge from SCT unit: D+ 80 (aged 15 months)

Page 17: HSCT in a patient with hyper IgM sy n drome  - our recent experience  -

ONDŘEJ Hemopoietic chimerism

0

20

40

60

80

100

14 28 42 49 62 73

days after SCT

% o

f allog

en

eic

h

em

op

oie

sis

T-cells 94% T-cells 92%

T-cells 71%

withdrawal of corticosteroids

D+53

withdrawal of CsA D+71

Page 18: HSCT in a patient with hyper IgM sy n drome  - our recent experience  -

ONDŘEJ 3 months after SCT

without immunosupressive treatment

no GVHD no signs of infection

stable mixed chimerism (50-55% of allogeneic hematopoiesis in PB;90-95% in T-lymphocytes)

Page 19: HSCT in a patient with hyper IgM sy n drome  - our recent experience  -

ONDŘEJ Team work Vlastimil Král Dalibor Jílek

Veronika Skalická Jakub Zieg Květa Bláhová Jan Lebl Renata Formánková Petr Sedláček Jan Starý Aleš Janda Jiřina Bartůňková Anna Šedivá

Genevieve de Saint Basile

Centre of Immunology and MicrobiologyÚstí n. L

Pediatric Clinic

Clinic of Pediatric Haematology and Oncology

Department of ImmunologyUniversity Hospital Motol, Prague

INSERM, Necker, Paříž